Background: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) may cause severe infections, often preceded by ESBL-E gastrointestinal (GI) colonization.
Methods: We conducted a review of the literature, investigating the prevalence of ESBL-E GI colonization in solid organ transplant (SOT) patients and the risk for subsequent ESBL-E infection. We searched the PubMed and EMBASE databases (to April 1, 2016) looking for studies that contained data on ESBL-E colonization among transplant patients.
Results: Of 341 non-duplicate citations, four studies reporting data on 1089 patients fulfilled our inclusion criteria. Among them, the pooled prevalence for ESBL-E colonization was 18% (95% confidence interval [CI] 5%-36%). Stratifying by transplant type, we identified an ESBL-E colonization rate of 17% (95% CI 3%-39%) among liver transplant recipients and 24% (single report) among kidney transplant recipients.
Conclusions: Among SOT patients, approximately one in five patients is colonized with ESBL-E, although this finding may be skewed by reporting bias from centers with high ESBL-E prevalence. ESBL-E screening in SOT patients should be considered and evaluated in future studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/tid.12718 | DOI Listing |
Genome Med
December 2024
Laboratory of Medical Microbiology, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.
Background: The impact of community carriage on the influx of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) into hospitals remains understudied. In this prospective 2-year single-centre study, we investigate the community ESBL-E influx and trace the colonisation, nosocomial acquisition, transmission, and infection dynamics of ESBL-producing Escherichia coli (ESBL-Ec) in non-ICU wards at a tertiary care hospital.
Methods: This study reports primary and post hoc outcomes of the clinical trial NCT01208519 in which hospitalised patients were screened for rectal carriage of ESBL-E.
Sci Rep
October 2024
Shanxi Medical University, Taiyuan, 030000, Shanxi, China.
Open Forum Infect Dis
October 2024
Department of Infectious Disease, Mercyhealth, Rockford, Illinois, USA.
Background: There are limited and conflicting data regarding the impact of race or ethnicity on the rate of gram-negative antimicrobial resistance. This study was performed to determine whether there is a difference in extended-spectrum beta-lactamase (ESBL) infection or colonization in minoritized patients when compared to White patients from a diverse US Midwestern city.
Methods: A case control study was performed, with controls with non-ESBL matched 1:1 to patients with ESBL-producing based on age, sex, and ZIP code.
JAC Antimicrob Resist
October 2024
Department of Pathology and Microbiology, School of Medicine, University of Zambia, Lusaka, Zambia.
Background: Surgical site infections (SSIs) are on the rise and are a global concern as they complicate the recovery of patients postoperatively. Bacterial colonization of the patient's skin and alimentary tract are known to be major contributing sources to SSIs. However, Zambia lacks data relating to carriage rates of antibiotic-resistant rectal among surgical patients.
View Article and Find Full Text PDFAm J Perinatol
October 2024
Department of Women's and Children's Health, Paediatric Inflammation, Metabolism and Child Health Research, Uppsala University, Uppsala, Sweden.
Objective: The aim of the study was to investigate the virulence factors in producing extended-spectrum β-lactamase (ESBL) derived from the perinatal fecal colonization flora of mothers and their newborns in a Chinese obstetric ward.
Study Design: Rectal swabs were obtained from mothers prenatally and from their newborns postnatally, and analyzed for ESBL-producing . The isolates were then whole-genome sequenced.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!